LD-2 disclosure · 1st Quarter - Report
OCERA THERAPEUTICS INC.
Client
- Name
- OCERA THERAPEUTICS INC.
- Description
- Biopharmaceutical product development & research
- Location
- California · United States of America
Registrant
- Description
- Global trade
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
3 issuesDefense
Funding for biopharmaceutical product development with the Department of Defense to treat long term health impact of chronic substance abuse.
Lobbyistsms WENDY SHELTON dvm · mr JAMES P FABIANI · ERIN FRY · mr STEPHEN R CONAFAY · MELISSA DUPREE
TargetedSENATE · HOUSE OF REPRESENTATIVES · Defense, Dept of (DOD) · Natl Institutes of Health (NIH)
Health Issues
Funding for biopharmaceutical product development to address nuclear warfare threats.
Lobbyistsms WENDY SHELTON dvm · mr JAMES P FABIANI · ERIN FRY · mr STEPHEN R CONAFAY · MELISSA DUPREE
TargetedSENATE · HOUSE OF REPRESENTATIVES · Defense, Dept of (DOD) · Natl Institutes of Health (NIH)
Budget/Appropriations
Fiscal Year 2010 Defense Appropriations Act. Funding for biopharmaceutical product trials for treatment to address long term health impact of substance abuse in military populations.
Lobbyistsms WENDY SHELTON dvm · mr JAMES P FABIANI · mr STEPHEN R CONAFAY · MELISSA DUPREE
SENATE · HOUSE OF REPRESENTATIVES · Defense, Dept of (DOD) · Natl Institutes of Health (NIH)